Cancer Science · 2018 · 33 citations · 20 references
MedicineMolecular GeneticsOncologyMolecular OncologyNeoplasiaOncogenesLung CancerMolecular Classification Of TumorsMutation AnalysisNext-generation Sequencing In OncologyOncogene MutationsTumor ClassificationCancer Mutation AnalysisLung Cancer ResectionMultiplex Mutation ScreeningMutational Spectrum AnalysisNext-generation Sequencing AnalysisTargeted Gene SequencingTargeted Next-generation SequencingTargeted Sequencing
In patients presenting with synchronous or metachronous multiple lung cancer (MLC), it is important to distinguish between multiple primary lung cancer (MP) and intrapulmonary metastasis (IM). The present study was aimed at investigating the mutational profiles of synchronous/metachronous MLC and to compare the classification of paired tumors by multiplex gene mutation analysis with the histopathological evaluation. We carried out targeted sequencing of 20 lung cancer-related oncogenes using next-generation sequencing (NGS) in 82 tumors from 37 MLC patients who underwent surgical resection at our department. The patients were diagnosed as MP or IM cases based on the Martini and Melamed criteria, histopathological and gene mutational evaluations. Matching mutations between paired tumors was observed in 20 (54%) patients, who were diagnosed as IM cases by mutational evaluation. Patients who could not be clearly diagnosed by histopathological evaluation were classified as equivocal cases. Among the histopathological IM cases (n = 7), six (86%) were confirmed as IM cases also by mutational evaluation, and most of the paired tumors of these cases (n = 5) harbored multiple matching mutations. Among the histopathological MP cases (n = 17), mutational evaluation yielded a discordant diagnosis in eight (47%) cases. Of these, the paired tumors of four cases harbored multiple matching mutations, suggesting that the mutational diagnosis might be more suitable in these patients. Our findings suggest that multiplex mutational analysis could be a useful complementary tool for distinguishing between MP and IM in addition to histopathological evaluation.
20
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi, Manabu Soda, Yuki Togashi et al. · Nature Medicine · 2012 · 1.3K citations
Nael Martini, Myron R. Melamed · Journal of Thoracic and Cardiovascular Surgery · 1975 · 1.3K citations
Intratumor Heterogeneity: Seeing the Wood for the Trees
Timothy A. Yap, Marco Gerlinger, P. Andrew Futreal et al. · Science Translational Medicine · 2012 · 502 citations
Medicine, Cancer Biology, Oncology +17